REG - PureTech Health PLC - PDMR Notification RSU Vesting

Puretech HealthAnnouncement

22/07/2022 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220722:nRSV3711Ta&default-theme=true

RNS Number : 3711T  PureTech Health PLC  22 July 2022

22 July 2022

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering, developing
and commercializing highly differentiated medicines for devastating diseases,
announces that awards of restricted share units ("RSUs") granted by PureTech
on 21 July 2021 to certain non-executive directors ("PDMRs") pursuant to its
Performance Share Plan ("PSP") vested in full on 15 June 2022 immediately
prior to the Company's Annual General Meeting of Stockholders. Each PDMR
received vested ordinary shares on 22 July 2022.

The Company's total issued ordinary share capital is 288,689,450 shares after
the share issuance to the PDMRs, 3,563,665 shares of which are held in
treasury by the Company.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance
with Article 19 of the EU Market Abuse Regulation.

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Raju Kucherlapati

                                                                  John LaMattina

                                                                  Robert Langer

                                                                  Kiran Mazumdar-Shaw

                                                                  Marjorie Scardino

                                                                  Christopher Viehbacher

 2   Reason for the notification
 a)  Position/status                                              Non-Executive Directors
 b)  Initial notification/Amendment                               Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         PureTech Health plc
 b)  LEI                                                          213800LVPDNO2Z9T9I39
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of PureTech Health plc

                                                                  ISIN GB00BY2Z0H74
 b)  Nature of the transaction                                    Issuance of ordinary shares in settlement of certain vested RSUs under the
                                                                  PureTech Health Performance Share Plan.
 c)  Price(s) and volume(s)                                       Recipient               Price     Amount
                                                                  Raju Kucherlapati       0.01 GBP  11,190 ordinary shares
                                                                  John LaMattina          0.01 GBP  11,190 ordinary shares
                                                                  Robert Langer           0.01 GBP  11,190 ordinary shares
                                                                  Kiran Mazumdar-Shaw     0.01 GBP  11,190 ordinary shares
                                                                  Marjorie Scardino       0.01 GBP  11,190 ordinary shares
                                                                  Christopher Viehbacher  0.01 GBP  11,190 ordinary shares
 d)  Aggregated information                                       Price     Aggregate Volume

- Aggregated volume                                         0.01 GBP  67,140 ordinary shares

- Price
 e)  Date of the transaction                                      22 July 2022
 f)  Place of the transaction                                     London Stock Exchange (XLON)

b)

Nature of the transaction

Issuance of ordinary shares in settlement of certain vested RSUs under the
PureTech Health Performance Share Plan.

c)

Price(s) and volume(s)

 Recipient               Price     Amount
 Raju Kucherlapati       0.01 GBP  11,190 ordinary shares
 John LaMattina          0.01 GBP  11,190 ordinary shares
 Robert Langer           0.01 GBP  11,190 ordinary shares
 Kiran Mazumdar-Shaw     0.01 GBP  11,190 ordinary shares
 Marjorie Scardino       0.01 GBP  11,190 ordinary shares
 Christopher Viehbacher  0.01 GBP  11,190 ordinary shares

d)

Aggregated information

 -  Aggregated volume

 -  Price

 Price     Aggregate Volume
 0.01 GBP  67,140 ordinary shares

e)

Date of the transaction

22 July 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated medicines
for devastating diseases, including inflammatory, fibrotic and immunological
conditions, intractable cancers, lymphatic and gastrointestinal diseases and
neurological and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its experienced
research and development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being advanced both
internally and through PureTech's Founded Entities, is comprised of 27
therapeutics and therapeutic candidates, including two that have received
both U.S. FDA clearance and European marketing authorization, as of the date
of PureTech's most recently filed Annual Report and corresponding Form 6-K.
All of the underlying programs and platforms that resulted in this pipeline
of therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based on unique
insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUMPMUPPGBG